Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 1136 results for pain

  1. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

  2. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

  3. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (NG237)

    This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.

  4. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  5. Intrathecal baclofen:- What is the clinical and cost effectiveness of continuous pump-administered intrathecal baclofen compared with usual care in children and young people who are at Gross Motor Function Classification System (GMFCS) level IV or V?

    treatments did not relieve difficulties associated with spasticity (specifically pain or muscle spasms, posture or function, or ease of...

  6. SecurAcath for securing cerebrospinal fluid catheters (MIB107)

    NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .

  7. Sacral nerve stimulation for faecal incontinence (IPG99)

    Evidence-based recommendations on sacral nerve stimulation for faecal incontinence. This involves using electrodes inserted under the skin to produce pulses of electricity thought to affect the nerves controlling the lower part of the bowel and the anal sphincter.

  8. Endoscopic submucosal dissection of gastric lesions (IPG360)

    Evidence-based recommendations on endoscopic submucosal dissection (ESD) of gastric lesions. This involves inserting a thin telescope through the mouth into the stomach to view the area and removing the lesion with special equipment.

  9. Measuring improvements in care home residents' oral health:- How can interventions to improve and maintain oral health and wellbeing, or to prevent dental disease, be measured using a patient-centred approach that can also be used to judge cost effectiveness?

    living in care homes and could include: - how much they value having a clean, pain-free, healthy mouth - how poor oral health may affect...

  10. Faecal microbiota transplant for recurrent Clostridioides difficile infection (MTG71)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  11. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  12. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  13. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  14. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

  15. Transperineal biopsy for diagnosing prostate cancer (DG54)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer